Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Beraprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 4/20 | 0.85 |
| ▸ | PTGER3 | P43115 | 13/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.39 |
| ▸ | PTGFR | P43088 | 12/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beraprost SCHEMBL4754472 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL11946708 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL1554142 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL4754473 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL16405382 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL6084946 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL16894023 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL22972690 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL21778834 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL19113984 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082154-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | CUORIPS INC. (JP) | 2024-03-14 | — | — | US | claimed |
| US-20210113464-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | CUORIPS INC. (JP) | 2021-04-22 | — | — | US | claimed |
| EP-3718537-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | Osaka University (JP) | 2020-10-07 | — | — | EP | claimed |
| US-20160250395-A1 | DRUG-ELUTING STENT GRAFT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-01 | — | — | US | claimed |
| US-20240082154-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | CUORIPS INC. (JP) | 2024-03-14 | — | — | US | disclosed |
| WO-2023088497-A2 | NITRIC OXIDE DONOR TYPE BERAPROST DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 广州楷石医药有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20230002339-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROM | CHIROGATE INTERNATIONAL INC. (TW) | 2023-01-05 | — | — | US | disclosed |
| EP-4098651-A1 | PROCESS FOR THE PREPARATION OF BERAPROST OR SIMILAR BENZOPROSTACYCLIN ANALOGUES STARTING FROM 2-(3-BROMO-2-FLUOROPHENYL)-4-HYDROXYCYCLOPENT-2-ENONE OR SIMILAR REACTANTS | Chirogate International Inc. (TW) | 2022-12-07 | — | — | EP | disclosed |
| CN-115433071-A | Methods and intermediates for preparing benzoprostacyclin analogs, and benzoprostacyclin analogs prepared therefrom | 佳和桂科技股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20210113464-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | CUORIPS INC. (JP) | 2021-04-22 | — | — | US | disclosed |
| EP-3718537-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | Osaka University (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200171026-A1 | PROSTACYCLIN RECEPTOR AGONISTS FOR REDUCTION OF BODY FAT | ALLERGAN INC (US) | 2020-06-04 | — | — | US | disclosed |
| US-8980944-B2 | EP2 and EP4 agonists as agents for the treatment of influenza a viral infection | GEMMUS PHARMA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8957240-B2 | Method for the purification of prostaglandins | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2015-02-17 | — | — | US | disclosed |
| US-8519178-B2 | Method for the purification of prostaglandins | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8519178-B2 | Method for the purification of prostaglandins | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8183286-B2 | EP2 and EP4 agonists as agents for the treatment of influenza a viral infection | GEMMUS PHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324313-A1 | METHOD FOR THE PURIFICATION OF PROSTAGLANDINS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20090170931-A1 | EP2 and EP4 agonists as agents for the treatment of influenza a viral infection | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | US | disclosed |
| US-7345181-B2 | Process for preparing prostaglandin derivatives and starting materials for the same | YONSUNG FINE CHEMICAL CO., LTD. (KR) | 2008-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171026-A1 | PROSTACYCLIN RECEPTOR AGONISTS FOR REDUCTION OF BODY FAT | PTGIR, PTGER1, PTGDR | PTGIR 1/4885PTGER3 10/4885PTGER2 5/4885 |
| US-20090170931-A1 | EP2 and EP4 agonists as agents for the treatment of influenza a viral infection | PTGER4, PTGER2, PTGER1 | PTGIR 11/4885PTGER3 4/4885PTGER2 2/4885 |
| US-20210113464-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | PTGDR2, PLA2R1, PTGDR | PTGIR 7/4885PTGER3 40/4885PTGER2 13/4885 |
| US-20230002339-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROM | PTGIS, PTGIR, PTGES | PTGIR 2/4885PTGER3 24/4885PTGER2 16/4885 |
| US-20240082154-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | LPAR2, PLA2R1, PTGDR2 | PTGIR 10/4885PTGER3 44/4885PTGER2 12/4885 |
| US-20100324313-A1 | METHOD FOR THE PURIFICATION OF PROSTAGLANDINS | PTGES, PTGES2, PTGS2 | PTGIR 9/4885PTGER3 6/4885PTGER2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.